Celldex Therapeutics (CLDX)

$29.45 -0.15 (-0.51%)
Market Cap 1.96B
Revenue (ttm) 7.02M
Net Income (ttm) -157.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,248.72%
Debt to Equity Ratio 0.00
Volume 1,067,600
Avg Vol 854,062
Day's Range N/A - N/A
Shares Out 66.45M
Stochastic %K 92%
Beta 1.13
Analysts Strong Sell
Price Target $53.14

Company Profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibit...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 200 7500
Fax: 908 454 1911
Address:
Perryville III Building, Suite 220 53 Frontage Road, Hampton, United States
NJgolfer
NJgolfer Dec. 5 at 12:13 AM
$CLDX new 52wk high and target looks like $34
0 · Reply
TheGunnerAB
TheGunnerAB Dec. 4 at 6:08 PM
$CLDX a new 52 week high! @RonIsWrong forgot to report so I'm filling in.
0 · Reply
Unburdened
Unburdened Dec. 4 at 4:09 PM
$CLDX Not sure what is causing the rise but thrilled by it
0 · Reply
lucabrix
lucabrix Dec. 4 at 4:03 PM
$CLDX Strong reaction!
0 · Reply
Steve1545
Steve1545 Dec. 4 at 3:34 PM
$CLDX breaking out
0 · Reply
BiotechValues
BiotechValues Dec. 3 at 8:34 PM
$JSPR all comes down to January data. You can tell they plan to deliver a win over $CLDX (that is the bar). Equal or better efficacy and a better safety profile
1 · Reply
MaverikIT
MaverikIT Dec. 3 at 5:12 PM
$CLDX - eyeing 52wk$ ​ ​$APGE $SRRK @Doozio
0 · Reply
lucabrix
lucabrix Dec. 3 at 3:55 PM
$CLDX Strong resistance to pass!
0 · Reply
Steve1545
Steve1545 Dec. 3 at 2:55 PM
$CLDX
1 · Reply
FactsPlease99
FactsPlease99 Nov. 28 at 12:05 PM
$CLDX Pretty interesting. This top rated analyst has 25 biotechs ratings in November and rated BUYS except one...CLDX rated a SELL...and the guy is a top notch rated analyst in biotech.
1 · Reply
Latest News on CLDX
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

Nov 10, 2025, 8:01 AM EST - 27 days ago

Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

Celldex to Present at Upcoming Investor Conferences

Nov 7, 2025, 8:01 AM EST - 4 weeks ago

Celldex to Present at Upcoming Investor Conferences

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

Sep 17, 2025, 5:11 AM EDT - 2 months ago

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

Celldex Therapeutics, Inc. (CLDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 12:20 PM EDT - 3 months ago

Celldex Therapeutics, Inc. (CLDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 9:01 AM EDT - 3 months ago

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track

Aug 21, 2025, 3:45 PM EDT - 3 months ago

Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track

Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short

Aug 20, 2025, 10:22 AM EDT - 3 months ago

Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

Aug 19, 2025, 4:01 PM EDT - 3 months ago

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 4:01 PM EDT - 4 months ago

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

Jun 14, 2025, 10:48 AM EDT - 6 months ago

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

Jun 12, 2025, 6:01 PM EDT - 6 months ago

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress

Jun 10, 2025, 4:01 PM EDT - 6 months ago

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

Jun 6, 2025, 8:01 AM EDT - 6 months ago

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 4:01 PM EDT - 7 months ago

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

May 5, 2025, 4:01 PM EDT - 7 months ago

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

Celldex Therapeutics to Present at Upcoming Investor Conferences

Mar 4, 2025, 8:01 AM EST - 9 months ago

Celldex Therapeutics to Present at Upcoming Investor Conferences

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

Mar 3, 2025, 8:01 AM EST - 9 months ago

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

Mar 1, 2025, 12:45 PM EST - 10 months ago

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 4:01 PM EST - 10 months ago

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

Dec 19, 2024, 8:01 AM EST - 1 year ago

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Nov 20, 2024, 8:01 AM EST - 1 year ago

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 6, 2024, 4:01 PM EST - 1 year ago

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market

Nov 4, 2024, 3:14 PM EST - 1 year ago

Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

Oct 26, 2024, 5:43 PM EDT - 1 year ago

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024

Oct 25, 2024, 8:01 AM EDT - 1 year ago

Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024

Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

Sep 25, 2024, 10:45 AM EDT - 1 year ago

Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024

Sep 16, 2024, 8:01 AM EDT - 1 year ago

Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024

Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

Jul 29, 2024, 4:01 PM EDT - 1 year ago

Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Jul 16, 2024, 8:01 AM EDT - 1 year ago

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics to Present at Jefferies Healthcare Conference

Jun 4, 2024, 4:01 PM EDT - 1 year ago

Celldex Therapeutics to Present at Jefferies Healthcare Conference

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024

Jun 2, 2024, 9:01 AM EDT - 1 year ago

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

May 15, 2024, 8:01 AM EDT - 1 year ago

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

Celldex Therapeutics: Rising High, With Room For Further Growth

May 10, 2024, 10:44 AM EDT - 1 year ago

Celldex Therapeutics: Rising High, With Room For Further Growth

Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 6, 2024, 4:01 PM EDT - 1 year ago

Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Apr 17, 2024, 8:01 AM EDT - 1 year ago

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Mar 8, 2024, 7:00 AM EST - 1 year ago

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Mar 5, 2024, 10:30 AM EST - 1 year ago

Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Mar 5, 2024, 10:10 AM EST - 1 year ago

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

Feb 29, 2024, 9:14 PM EST - 1 year ago

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

Feb 28, 2024, 4:01 PM EST - 1 year ago

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 26, 2024, 7:01 AM EST - 1 year ago

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

Feb 24, 2024, 2:05 PM EST - 1 year ago

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 6, 2024, 4:01 PM EST - 1 year ago

Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024

Feb 5, 2024, 8:01 AM EST - 1 year ago

Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024

MoneyShow's Best Investment Ideas For 2024: Part 3

Jan 29, 2024, 10:45 AM EST - 2 years ago

MoneyShow's Best Investment Ideas For 2024: Part 3

CFR CHRD CROX CTO GLW LEU SCHW

MoneyShow's Best Investment Ideas For 2024: Part 2

Jan 26, 2024, 5:30 PM EST - 2 years ago

MoneyShow's Best Investment Ideas For 2024: Part 2

ANET BAX BIP BLK BP CCJ CSTE

Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference

Nov 27, 2023, 4:15 PM EST - 2 years ago

Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference

Celldex: Mast Cell Disease Targeting Continues To Make Advancements In Clinic

Nov 8, 2023, 3:22 PM EST - 2 years ago

Celldex: Mast Cell Disease Targeting Continues To Make Advancements In Clinic

Celldex Therapeutics Announces Pricing of Public Offering of Common Stock

Nov 7, 2023, 11:15 PM EST - 2 years ago

Celldex Therapeutics Announces Pricing of Public Offering of Common Stock

NJgolfer
NJgolfer Dec. 5 at 12:13 AM
$CLDX new 52wk high and target looks like $34
0 · Reply
TheGunnerAB
TheGunnerAB Dec. 4 at 6:08 PM
$CLDX a new 52 week high! @RonIsWrong forgot to report so I'm filling in.
0 · Reply
Unburdened
Unburdened Dec. 4 at 4:09 PM
$CLDX Not sure what is causing the rise but thrilled by it
0 · Reply
lucabrix
lucabrix Dec. 4 at 4:03 PM
$CLDX Strong reaction!
0 · Reply
Steve1545
Steve1545 Dec. 4 at 3:34 PM
$CLDX breaking out
0 · Reply
BiotechValues
BiotechValues Dec. 3 at 8:34 PM
$JSPR all comes down to January data. You can tell they plan to deliver a win over $CLDX (that is the bar). Equal or better efficacy and a better safety profile
1 · Reply
MaverikIT
MaverikIT Dec. 3 at 5:12 PM
$CLDX - eyeing 52wk$ ​ ​$APGE $SRRK @Doozio
0 · Reply
lucabrix
lucabrix Dec. 3 at 3:55 PM
$CLDX Strong resistance to pass!
0 · Reply
Steve1545
Steve1545 Dec. 3 at 2:55 PM
$CLDX
1 · Reply
FactsPlease99
FactsPlease99 Nov. 28 at 12:05 PM
$CLDX Pretty interesting. This top rated analyst has 25 biotechs ratings in November and rated BUYS except one...CLDX rated a SELL...and the guy is a top notch rated analyst in biotech.
1 · Reply
FactsPlease99
FactsPlease99 Nov. 26 at 4:44 PM
$CLDX posted on this board to buy ARWR many months ago $20 s ...today $56.... Sold my CLDX and added even ARWR in the $30 and $40 range.
1 · Reply
lucabrix
lucabrix Nov. 17 at 3:57 PM
$CLDX 50SMA in, can go up to 30
0 · Reply
lucabrix
lucabrix Nov. 14 at 8:55 PM
$CLDX nice strong weekly close!!
0 · Reply
lucabrix
lucabrix Nov. 14 at 4:43 PM
$CLDX Reply!!
0 · Reply
allen02
allen02 Nov. 12 at 12:31 PM
$CLDX Bullish Engulfing Candlestick Pattern.
0 · Reply
lucabrix
lucabrix Nov. 11 at 9:38 PM
$CLDX Stifel maintained its Buy rating and $58.00 price target on Celldex Therapeutics following the company’s third-quarter 2025 update. CLDX shows significant upside potential against Stifel’s target, with analyst consensus remaining bullish and the highest price target reaching $90. InvestingPro data indicates the company is slightly undervalued based on its Fair Value assessment.
0 · Reply
lucabrix
lucabrix Nov. 11 at 3:51 PM
$CLDX Told you, here we go!
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 3:03 PM
Barclays updates rating for Celldex Therapeutics ( $CLDX ) to Underweight, target set at 25 → 21.
0 · Reply
Estimize
Estimize Nov. 10 at 11:51 PM
$CLDX reported -1.01 EPS and 0.00 revenue for Q3. http://www.estimize.com/intro/cldx?chart=historical&metric_name=eps&utm_content=CLDX&utm_
0 · Reply
free2dream
free2dream Nov. 10 at 9:27 PM
$CLDX data has been great but how long will this shit take to be approved ?
0 · Reply
lucabrix
lucabrix Nov. 10 at 4:10 PM
$CLDX We are thrilled to welcome Teri Lawver to our leadership team as SVP & CCO. With a notable record of success across global biopharma & medtech companies, Teri's experience will be invaluable as we prepare for the potential launch of barzolvolimab - Here we go!!
0 · Reply
lucabrix
lucabrix Nov. 6 at 4:01 PM
$CLDX Celldex Therapeutics (NASDAQ:CLDX) on Thursday announced new exploratory endpoint data demonstrating barzolvolimab’s ability to improve urticaria control in patients with chronic spontaneous urticaria (CSU). The data, presented at the American College of Allergy, Asthma & Immunology’s Annual Scientific Meeting in Orlando, showed significant improvements in the urticaria control test over seven days (UCT7) scores among patients receiving the treatment. Patients on barzolvolimab experienced up to an 8.6-point improvement from baseline UCT7 scores compared to 2.5 points for placebo at Week 12. This improvement increased to 10.0 points at Week 52, according to the company.
0 · Reply